PubMed Health⌕ Search

PubMed · 11838525

Measuring academic production.

Abstract

BACKGROUND: The entire academic medical community is under increasing pressure to define and measure its activities. Previous relative value-based systems to measure research, teaching, administration, and patient care share several features that threaten their acceptability and validity. Using a bottom-up approach, our academic family medicine department attempted to develop a measurement system that avoided some of the flaws of the earlier systems. METHODS: The system was developed in two phases. In the first phase, faculty members were invited to submit lists of all their professional activities. In the second phase, the faculty rated the relative value of a comprehensive list of academic activities using an unbounded ratio scale and indicated how many times a year they did each activity. RESULTS: Phase One resulted in a list of 96 academic activities. The activity rated in Phase Two as having the greatest relative value was principal investigator of a funded grant (relative value=30.23), followed by sole author of a book (relative value=28.25). The activity with the smallest relative value was attending a faculty meeting (relative value=.36). A half-day clinic session had a relative value of 1.08. The department's annual production, measured in relative value units, was 5,764 units of administration, 5,702 units of clinical activities, 5,480 units of teaching, and 4,401 units of scholarly activities. CONCLUSIONS: Overall, the process efficiently produced relative value measures for a large number of faculty activities using a process in which most of the faculty participated. Problems with internal coherence, face validity, and inconsistencies in estimation suggest it would be premature to use such estimates of relative value to quantify individuals 'productivity as a basis for budgetary decisions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dewey C Scheid, Robert M Hamm, Steven A Crawford. 2002. Measuring academic production.. https://pubmed.ncbi.nlm.nih.gov/11838525/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Challenges in drug development for muscle disease: a stakeholders' meeting.

Current treatment benefits for patients with muscle disease are limited, but progress in legislative and scientific initiatives have set the stage for the development of new therapies. The MD-CARE Act (Public Law 107-84), which allocates federal resources to muscular dystrophy, was approved by Congress and signed into law by the President of the United States in 2001. This has shifted the emphasis toward translational research. To facilitate a push toward therapy for muscle disorders, the Muscular Dystrophy Association (MDA) sponsored a meeting with representatives from industry, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and other government agencies and academia. Each contributed in different ways. The FDA helped define the necessary data to support investigational new drug (IND) applications including the design of proof-of-principle studies, outcome measures for clinical trials, and the pathway for developing surrogate measures for fast-tracking promising new drugs. The NIH, other government agencies, and the MDA described potential funding sources for translational research. Industry delineated a complementary role with academia, and academic investigators elucidated the current strengths and weaknesses of available clinical endpoints. The meeting provided a format for communication for diverse disciplines that usually have no common meeting ground, helping to lay the foundation for bringing products to market in a timely fashion.

Academic Medical Centers↗

Reporting of adverse drug reactions: predictors of under-reporting in Malaysia.

BACKGROUND: Malaysia like many other countries worldwide uses spontaneous reporting systems as a mean of collecting data on suspected adverse drug reaction (ADR). However, compared to other countries, which use the system, the reporting rate in Malaysia is very low. Why some physicians do not report ADRs is not well understood. OBJECTIVE: To identify factors, which would predict physicians' failure to send ADR reports. DESIGN AND SETTING: Face-to-face interview using a structured questionnaire involving physicians working at the University of Malaya Medical Centre, Malaysia. RESULTS: About a third of the physicians in the Centre participated. Sixty-five of the 415 approached refused to participate. A high proportion of the respondents (81.4%) indicated that they had suspected an ADR but did not report it, while about 40% of the respondents were not aware of the existence of the national reporting system in Malaysia. Logistic regression modelling identified the variable 'ADR considered to be too trivial or too well known to report' as the strongest predictor of not reporting, followed by physicians' category and uncertainty that the reaction had been definitely caused by a drug. CONCLUSION: Important predictor variables, which limit physicians from reporting ADR in Malaysia, were related to uncertainty of types of reaction to report, lack of awareness about the existence, function and purpose of national ADR reporting. The findings could be useful for planning strategies to improve the reporting rate.

Academic Medical Centers↗